ClinicalTrials.gg
RecruitingNCT06214065Updated Mar 27, 2026

Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)

An interventional study of fMRI and rTMS in Autism Spectrum Disorder, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Yale University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Autism Spectrum Disorder by Yale University — 3 open to participants now, 4 under way, none of them phase 3. Autism Spectrum Disorder · Yale University.

Planned enrollment
4th of 20
80 · median 40
Started
2024
with 2 others
No phase
18 of 24
3 open now
Registered
23rd of 24
by date

Among the 24 studies in Autism Spectrum Disorder by Yale University, this one is the 4th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 18 with no phase, and was the 23rd registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

3 of the 24 studies in Autism Spectrum Disorder by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Autism Spectrum Disorder by Yale University, or all of them as a file.
02

Study summary

The goal of this observational study is to test the modulation effect of different transcranial magnetic stimulation (TMS) on the neural network supporting our ability to create mental representations of others (also known as mentalizing) in young adults with autism. The main question it aims to answers is can stimulation of the right temporoparietal junction can change brain activity related to mentalizing during social interaction in the stimulation area and other brain areas connected to it. Researchers will compare results to a group of individuals without autism to see if the patterns of neural activity change are similar between the groups.

Participants will undergo assessment of their clinical traits and social skills and baseline MRI scan. They will attend three additional visits that include TMS session and functional MRI scans before and right after TMS.

Read the detailed description

All participants will be scheduled for four study sessions that include a baseline and three subsequent sessions that will each include two functional magnetic resonance imaging (fMRI) scans, one pre and one post an rTMS session.

During each fMRI scan, participants will be engaged in intersocial, competitive Domino task that involves mentalizing. rTMS manipulation, administered in a double-blind, counterbalanced fashion, includes one session each of excitatory (intermittent theta-burst stimulation, iTBS), inhibitory (continuous TBS, cTBS), and sham sequences. The rTMS will be guided with individualized electric-field modeling calculated from a structural MRI scan collected on the baseline session. This robust design is necessary to identify the optimal rTMS sequence to engage the right TPJ and the mentalizing network in ASD because firm conclusions about how best to modulate this network cannot be drawn from the few known published reports.

Investigators hypothesize that iTBS will result in increased, while cTBS in decreased MTR neural activity in the mentalizing network, with this being more pronounced in ASD, and sham resulting in no change. Understanding this mechanism will be the first and crucial step in validating rTMS of the right TPJ as a viable neural target to modulate neural circuit, and subsequently to modulate social-communication skills in ASD in future clinical studies. The significance of such a line of research should be considered in the context of the high prevalence of ASD and the dire need of developing effective interventions, especially for adults.

The three rTMS sessions will be compared within-subject and between-groups.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Estimated full-scale IQ>80
  • Right handed
  • Fluent in English
  • Individual can cooperate with all study's procedures
  • No history of neurological disorder (e.g. epilepsy) or neurosurgery
  • No major medical condition (e.g. cancer, heart failure)
  • No history of significant head injury
  • No primary relatives with history of any neurological disorder with a potentially hereditary basis, including epilepsy or MS
  • No current use of medications with psychotropic (e.g., benzodiazepines) or anti- or pro-convulsants
  • No current substance use (determined by urine screen and breathalyzer in all visits)
  • Negative urine pregnancy (women) test at time of MRI scans
  • No MR (e.g. in-body metal implant, severe claustrophobia)
  • No previous participation in our lab in a study including the Domino fMRI task
  • For ASD: Stable medication treatment 4 weeks prior to study enrollment
  • For Control Group: No current or history of psychiatric disorders, other than simple phobia, and/or primary relatives with ASD

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    ASD: excitatory, then inhibitory, then sham rTMS

    Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.

    Diagnostic Test: fMRI · Device: rTMS

  • Experimental
    Typically Developing (TD): excitatory, then inhibitory, then sham rTMS

    Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.

    Diagnostic Test: fMRI · Device: rTMS

Interventions

  • Diagnostic testfMRI

    fMRI will be performed pre- and post-rTMS

  • DevicerTMS

    TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.

06

What researchers measure

Primary outcomes

  1. Mentalizing Task Related (MTR) neural activity in the mentalizing network

    Change in MTR activity in six brain regions, from fMRI scans will be measured pre- to post-rTMS.

    Time frame: during each fMRI, up to 5 hours

07

Study locations

1 of 1 sites recruiting
  • Olin Neuropsychiatry Research Center (ONRC)
    Hartford, Connecticut 06106, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All investigators are aware of and agree to abide by the principles for sharing research resources, as described by NIH in "Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Programs." Specifically, all data collected in this study, including demographic information, psychiatric, symptom, cognitive and social assessments as well as MRI imaging data, will be shared with the scientific community through the National Institute of Mental Health Data Archive (NDA).

Access criteria: National Institute of Mental Health Data Archive (NDA)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2027, 42 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 42 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 19, 2024
StartActual
Apr 3, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06214065
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Apr 3, 2024
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Michal Assaf, MD
Contact
michal.assaf@hhchealth.org
860-545-7792
Vaughn R Steele, MD
Contact
vaughn.steele@yale.edu
860-545-7855
Vaughn Steele, MD
principal investigator · Yale University
Michal Assaf, MD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion